Molecular imaging and therapy of somatostatin receptor positive tumors

Jana Ivanidze, Michelle Roytman, Arielle Sasson, Myrto Skafida, Thomas J. Fahey, Joseph R. Osborne, Silvina P. Dutruel

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Somatostatin receptors (SSTR)are upregulated in the cells of origin that define numerous neuroendocrine neoplasms. PET imaging with 68Ga-DOTATATE allows specific targeting of SSTR2A, a single species of SSTR receptor, which is commonly overexpressed in a variety of gastroenteropancreatic neuroendocrine tumors, as well as pulmonary carcinoid and head and neck tumors. Due to more specific targeting of SSTR2 as well as lower radiation dose, shorter study length, ability to quantify uptake, and lower cost, 68Ga-DOTATATE has demonstrated superior imaging attributes when compared to 111In-pentetreotide. As with any novel imaging modality, dedicated training, increasing experience and staying up-to-date with scientific publications are required to provide optimal patient care. The purpose of this review is to summarize the current state of the art in SSTR-targeted molecular imaging and discuss ongoing and future potential diagnostic and therapeutic applications.

Original languageEnglish
Pages (from-to)146-154
Number of pages9
JournalClinical Imaging
StatePublished - 1 Jul 2019
Externally publishedYes


  • Neuroendocrine tumors
  • Somatostatin receptors


Dive into the research topics of 'Molecular imaging and therapy of somatostatin receptor positive tumors'. Together they form a unique fingerprint.

Cite this